333 related articles for article (PubMed ID: 35056105)
21. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.
Schwartz DM; Bonelli M; Gadina M; O'Shea JJ
Nat Rev Rheumatol; 2016 Jan; 12(1):25-36. PubMed ID: 26633291
[TBL] [Abstract][Full Text] [Related]
22. Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
Klein K; Stoiber D; Sexl V; Witalisz-Siepracka A
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073410
[TBL] [Abstract][Full Text] [Related]
23. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
24. JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus.
Moysidou GS; Dara A
Mediterr J Rheumatol; 2024 Mar; 35(Suppl 1):37-44. PubMed ID: 38756931
[TBL] [Abstract][Full Text] [Related]
25. JAK-STAT inhibitors for the treatment of immunomediated diseases.
Serra López-Matencio JM; Morell Baladrón A; Castañeda S
Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
[TBL] [Abstract][Full Text] [Related]
26. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Kotyla PJ
Biomed Res Int; 2018; 2018():7492904. PubMed ID: 29862290
[TBL] [Abstract][Full Text] [Related]
27. Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity.
Alim K; Bruyère A; Lescoat A; Jouan E; Lecureur V; Le Vée M; Fardel O
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):259-271. PubMed ID: 33292029
[No Abstract] [Full Text] [Related]
28. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.
Rocha CM; Alves AM; Bettanin BF; Majolo F; Gehringer M; Laufer S; Goettert MI
Inflammopharmacology; 2021 Jun; 29(3):595-615. PubMed ID: 34046798
[TBL] [Abstract][Full Text] [Related]
29. JAK/STAT pathway in pathology of rheumatoid arthritis (Review).
Ciobanu DA; Poenariu IS; Crînguș LI; Vreju FA; Turcu-Stiolica A; Tica AA; Padureanu V; Dumitrascu RM; Banicioiu-Covei S; Dinescu SC; Boldeanu L; Siloși I; Ungureanu AM; Boldeanu MV; Osiac E; Barbulescu AL
Exp Ther Med; 2020 Oct; 20(4):3498-3503. PubMed ID: 32905201
[TBL] [Abstract][Full Text] [Related]
30. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
31. [The next step in the treatment of immune diseases: jakinibs, inhibitors of the intracellular Janus kinase].
van de Laar MAFJ; Hoentjen F; Thio HB
Ned Tijdschr Geneeskd; 2019 Aug; 163():. PubMed ID: 31433146
[TBL] [Abstract][Full Text] [Related]
32. Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs.
Zhao MY; Zhang W; Rao GW
Curr Med Chem; 2022 Aug; 29(29):5010-5040. PubMed ID: 35255783
[TBL] [Abstract][Full Text] [Related]
33. Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies.
Kogame T; Egawa G; Kabashima K
Immunol Med; 2023 Sep; 46(3):112-120. PubMed ID: 37254967
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic potential of JAK/STAT pathway modulation in mood disorders.
Shariq AS; Brietzke E; Rosenblat JD; Pan Z; Rong C; Ragguett RM; Park C; McIntyre RS
Rev Neurosci; 2018 Dec; 30(1):1-7. PubMed ID: 29902157
[TBL] [Abstract][Full Text] [Related]
35. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
Svoboda SA; Johnson N; Phillips M
Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
[TBL] [Abstract][Full Text] [Related]
36. Translating JAKs to Jakinibs.
Gadina M; Chisolm DA; Philips RL; McInness IB; Changelian PS; O'Shea JJ
J Immunol; 2020 Apr; 204(8):2011-2020. PubMed ID: 32253269
[TBL] [Abstract][Full Text] [Related]
37. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y; Alexander M; Gadina M; O'Shea JJ; Meylan F; Schwartz DM
J Allergy Clin Immunol; 2021 Oct; 148(4):911-925. PubMed ID: 34625141
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Yang F; Lu C; Wang Y; Liu H; Leng X; Zeng X
Clin Rheumatol; 2023 Jun; 42(6):1593-1605. PubMed ID: 36763226
[TBL] [Abstract][Full Text] [Related]
39. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
40. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs.
Gadina M; Johnson C; Schwartz D; Bonelli M; Hasni S; Kanno Y; Changelian P; Laurence A; O'Shea JJ
J Leukoc Biol; 2018 Sep; 104(3):499-514. PubMed ID: 29999544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]